Effect of osimertinib in ethnic Chinese with EGFR and T790M mutated NSCLC

Trial Identifier:	D5160R00016
Sponsor:	AstraZeneca
NCTID::	NCT03133234
Start Date:	May 2017
Primary Completion Date:	September 2017
Study Completion Date:	September 2017

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Macau, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.